Sjögren’s syndrome

Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren's syndrome in a phase 2 study.

Findings from a phase 1/2 pilot study suggest that baricitinib may be a promising treatment option for primary Sjögren's syndrome.

EULAR has issued recommendations for managing cardiovascular risk in people with antiphospholipid syndrome, gout, mixed connective tissue disease, myositis, Sjögren’s syndrome, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

Extended phase 2b follow-up data show that ianalumab is well tolerated for at least 1 year in people with primary Sjögren’s syndrome, and prolonging treatment beyond 6 months leads to further improvements in efficacy outcomes.

People who develop early-onset primary Sjögren’s syndrome have “strikingly more severe disease activity” and greater activation of the cellular immune system compared with those diagnosed at a later age, researchers report.

Subcutaneous belimumab combined with intravenous rituximab is well tolerated by patients with primary Sjögren's syndrome and shows positive signs of efficacy, suggest phase 2 study results.

Findings from the Euro-COVIMID study suggest that the seroprevalence and effects of SARS-CoV-2 infection in patients with rheumatic diseases are in line with those in the general population, and inflammation may be a risk factor for developing symptomatic COVID-19.

A large US study has evaluated the risk for developing incident rheumatic disease following a positive test for SARS-CoV-2.

Treatment with the IL-6 receptor inhibitor tocilizumab does not improve clinical outcomes for patients with primary Sjögren’s syndrome, suggest findings from the ETAP trial.

Phase 3 trial results indicate that abatacept does not have significant clinical efficacy in patients with moderate-to-severe active primary Sjögren’s syndrome.

Treatment with the selective PI3K-delta inhibitor seletalisib may reduce disease activity in patients with moderate-to-severe primary Sjögren’s syndrome, suggest data from a phase 2 proof-of-concept study.